HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The SNP rs9677 of VPAC1 gene is associated with glycolipid control and heart function in female patients with type 2 diabetes: A follow-up study.

AbstractBACKGROUND AND AIMS:
In a previous study, the single-nucleotide polymorphism (SNP) rs9677, mapped in the 3'-UTR of vasoactive intestinal peptide receptor 1 (VPAC1) gene, was found to be associated with type 2 diabetes (T2D) in Caucasian women. Moreover, the CC genotype correlated with a worse glycolipid profile. The objectives of this study were to confirm this correlation and assess the prevalence of coronary artery disease (CAD) in the previously investigated diabetic women after a follow-up of 4.6 years.
METHODS AND RESULTS:
A total of 143 women with T2D, with 53 carrying the CC genotype (age: 71.7 ± 7.4 years, diabetes duration: 17.2 ± 9.9 years) and 90 carrying the CT + TT genotypes (age: 69.4 ± 8.8 years, diabetes duration: 14.3 ± 8.2 years), were followed up for 4.6 ± 1.8 years. At follow-up, the clinical and haematochemical parameters were analysed. Twelve-lead electrocardiography, Doppler echocardiography and the percentage of patients with acute myocardial infarction (AMI) or of those subjected to coronary angioplasty and coronary artery bypass surgery were evaluated. At follow-up, there was no significant difference in terms of the clinical and haematochemical parameters between the two groups. However, despite a significantly increased use of statin therapy, no significant improvement in the LDL cholesterol levels was observed in CC female patients unlike those with CT + TT (P = 0.02). Moreover, the CC female patients presented a significantly higher percentage of echocardiographic abnormalities (P = 0.035), especially left ventricular (LV) diastolic dysfunction (P = 0.04).
CONCLUSIONS:
The rs9677 CC genotype could be correlated with a reduced response to statin therapy and seems to be involved in diabetes cardiomyopathy in female patients with T2D.
AuthorsF Tavaglione, T Filardi, M Fallarino, E Mandosi, I Turinese, M Rossetti, A Lenzi, S Morano
JournalNutrition, metabolism, and cardiovascular diseases : NMCD (Nutr Metab Cardiovasc Dis) Vol. 26 Issue 2 Pg. 109-13 (Feb 2016) ISSN: 1590-3729 [Electronic] Netherlands
PMID26712708 (Publication Type: Journal Article)
CopyrightCopyright © 2015 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.
Chemical References
  • 3' Untranslated Regions
  • Biomarkers
  • Cholesterol, LDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Receptors, Vasoactive Intestinal Polypeptide, Type I
  • VIPR1 protein, human
Topics
  • 3' Untranslated Regions
  • Aged
  • Angioplasty, Balloon, Coronary
  • Biomarkers (blood)
  • Cholesterol, LDL (blood)
  • Coronary Artery Bypass
  • Coronary Artery Disease (ethnology, genetics, physiopathology, therapy)
  • Diabetes Mellitus, Type 2 (diagnosis, ethnology, genetics)
  • Diabetic Angiopathies (ethnology, genetics, physiopathology, therapy)
  • Diabetic Cardiomyopathies (ethnology, genetics, physiopathology, therapy)
  • Dyslipidemias (blood, drug therapy, ethnology, genetics)
  • Echocardiography, Doppler
  • Electrocardiography
  • Female
  • Follow-Up Studies
  • Gene Frequency
  • Genetic Association Studies
  • Genetic Predisposition to Disease
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use)
  • Italy (epidemiology)
  • Middle Aged
  • Myocardial Infarction (ethnology, genetics, physiopathology)
  • Phenotype
  • Polymorphism, Single Nucleotide
  • Prevalence
  • Receptors, Vasoactive Intestinal Polypeptide, Type I (genetics)
  • Risk Factors
  • Time Factors
  • Ventricular Dysfunction, Left (ethnology, genetics, physiopathology)
  • White People (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: